Johnson & Johnson $JNJ Position Lessened by WoodTrust Financial Corp

WoodTrust Financial Corp lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 69,311 shares of the company’s stock after selling 2,216 shares during the quarter. Johnson & Johnson makes up approximately 2.2% of WoodTrust Financial Corp’s holdings, making the stock its 15th biggest holding. WoodTrust Financial Corp’s holdings in Johnson & Johnson were worth $18,349,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Auto Owners Insurance Co boosted its holdings in shares of Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares during the last quarter. Jupiter Topco LLC acquired a new position in Johnson & Johnson in the second quarter valued at $1,967,399,000. Diamant Asset Management Inc. lifted its position in Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after buying an additional 4,454,778 shares during the period. Corient Private Wealth LP lifted its position in Johnson & Johnson by 127.3% during the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock worth $1,539,292,000 after buying an additional 3,393,981 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after buying an additional 2,513,321 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported strong two-year Phase 3 ICONIC-LEAD results for ICOTYDE (icotrokinra) in moderate-to-severe plaque psoriasis. Nearly three-quarters of patients achieved clear or almost clear skin after two years, while the treatment maintained a favorable safety profile. The data support ICOTYDE’s potential as a differentiated oral psoriasis therapy and could strengthen JNJ’s future pharmaceutical growth. Johnson & Johnson ICOTYDE two-year results
• Positive Sentiment: Guggenheim reaffirmed its Buy rating, while Morgan Stanley also issued a Buy rating. The analyst support adds to the positive sentiment surrounding JNJ’s earnings outlook and pipeline investments. Guggenheim reaffirms Buy rating
• Positive Sentiment: Several articles highlighted JNJ’s established dividend-growth record and viewed the company as a relatively dependable income investment. That defensive appeal may attract investors seeking stability ahead of quarterly results. Healthcare Dividend Aristocrats
• Neutral Sentiment: JNJ is approaching its third-quarter earnings report. Analysts expect strong drug sales and contributions from newer launches, but investors will focus on whether Stelara biosimilar competition and Medical Technology weakness affect growth. J&J Q3 earnings outlook
• Negative Sentiment: JNJ faces a longer-term patent-cliff risk as exclusivity for major cancer drugs Imbruvica and Darzalex approaches expiration, potentially pressuring pharmaceutical revenue unless pipeline products and acquisitions offset the loss. Johnson & Johnson patent cliff
• Negative Sentiment: Boston Scientific is suing JNJ subsidiary Atraverse over alleged patent infringement involving the Hotwire cardiology system, seeking an injunction and damages. The case introduces potential legal costs and disruption for the Medical Technology business. Boston lawsuit against J&J subsidiary

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.9%

JNJ stock traded up $4.77 during midday trading on Friday, reaching $261.25. 1,960,164 shares of the company’s stock traded hands, compared to its average volume of 7,940,997. The company has a market capitalization of $629.60 billion, a P/E ratio of 30.25, a PEG ratio of 2.59 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The business has a 50-day moving average price of $265.73 and a two-hundred day moving average price of $248.93.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the prior year, the business earned $2.77 earnings per share. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.3 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on JNJ shares. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 15th. HSBC raised their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Scotiabank reaffirmed an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Johnson Rice reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $276.22.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.